10810711

=> s l18
L19 1 L18

=> d l19, ibib abs hitstr, 1

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:800851 HCAPLUS
DOCUMENT NUMBER: 141:314170
TITLE: 4-Substituted quinoline derivatives, the preparation thereof and compositions containing same, useful as antimicrobials
INVENTOR(S): Bigot, Antony; El Ahmad, Youssef; Malleron, Jean Luc; Martin, Jean Paul; Mignani, Serge; Pantel, Guy; Ronan, Baptiste; Tabart, Michel
PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.
SOURCE: Fr. Demande, 67 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2852954	A1	20041001	FR 2003-3812	20030328
FR 2852954	B1	20060714		
US 2004224946	A1	20041111	US 2004-810711	20040326
AU 2004226207	A1	20041014	AU 2004-226207	20040329
CA 2520764	AA	20041014	CA 2004-2520764	20040329
WO 2004087647	A2	20041014	WO 2004-FR783	20040329
WO 2004087647	A3	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1611127	A2	20060104	EP 2004-742385	20040329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1795191	A	20060628	CN 2004-80014510	20040329

PRIORITY APPLN. INFO.:

FR 2003-3812	A	20030328
US 2003-487084P	P	20030714
WO 2004-FR783	W	20040329

OTHER SOURCE(S): MARPAT 141:314170
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Quinoline-4-substituted derivs. I are disclosed [wherein X, Y, Z, U, T = C-R1' to CR5' resp., or one or more is a N atom; R1, R1', R2', R3', R4',

Updated Search

R5' = independently H, halo, cyclo/alkyl, Ph,phenylthio, mono or bicyclic hetero(aryl)thio, OH and derivs., SH and derivaitves, NH2 and derivaitves, acyl, OCF3, OCHF2, CN, CO2H and derivaitves, NO2, etc.; D = CHR, CO, CROH, CRF, CF2; R = H, alkyl; A = (CH2)m; m = 1-3; B = (CH2)n; n = 0-2; E = CH2, and when Z = O, S, SO, SO2, then n = 2; R2 = CO2R, CH2CH2CO2R, CH2OH, CH2CH2OH, where R is defined as above; R3 = Ph, mono or bicyclic heteroaryl, alkylene-R3'', etc.; R3'' = H, halo, OH and derivs., alkylthio, akylsulfinyl, alkylsulfonyl, alkylamino, cycloalkyl, acyl, Ph, OPh, heteroaryloxy, mono and bicyclic heteroaryl, NH2 and derivs., CONH2 and derivs., etc.; their enantiomers or diastereoisomers or their mixts., and/or their syn or anti forms or their mixts.; and their salts]. The novel derivs. are particularly interesting as antimicrobial agents. For example, II was prepared by amination of 2-[(E)-3-chloro-1-propenyl]-1,4-difluorobenzene (preparation given) with amine salt III•2HCl, followed by acidic hydrolysis. Compds. I were active against exptl. infections of mice by Staphylococcus aureus IP 8203 at 5-50 mg/kg s.c. or orally. None of the compds. showed toxicity in mice at 50 mg/kg s.c. (2 administrations).

IT 767355-37-3P, 2-[3-(3-Fluoro-6-methoxyquinolin-4-yl)propyl]morpholine-2-carboxylic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 4-substituted quinolines as antimicrobials)

RN 767355-37-3 HCAPLUS

CN 2-Morpholinecarboxylic acid, 2-[3-(3-fluoro-6-methoxy-4-quinolinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT